Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension

Format

• Summary
• Summary (text)
• Abstract
• Abstract (text)
• MEDLINE
• XML
• PMID List

2016 Jul 15;118(2):292-7. doi: 10.1016/j.amjcard.2016.04.028. Epub 2016 May 5.

Abstract

It has been suggested that lipoprotein abnormalities may contribute to the pulmonary arteriolar dysfunction observed in pulmonary arterial hypertension (PAH). High-density lipoprotein cholesterol (HDL) has vasodilatory, anti-inflammatory, and endothelial protective properties. We hypothesized that a higher serum HDL level may be advantageous for survival in PAH and that the serum HDL level at diagnosis would be an independent predictor of survival in PAH and be additive to previously validated predictors of survival. This study included all patients with PAH seen at the Mayo Clinic Pulmonary Hypertension Clinic from January 1, 1995, to December 31, 2009, who had a baseline HDL measurement. Mortality was analyzed over 5 years using the Kaplan-Meier method. Univariate and multivariable Cox proportional hazards ratios were calculated to evaluate the relation between baseline HDL level and survival. HDL levels were available for 227 patients. Higher HDL levels were associated with significantly lower mortality. Patients with an HDL >54 mg/dl at diagnosis had a 5-year survival of 59%.


In conclusion, HDL was an independent predictor of survival in PAH.
 

¹Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.

²Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address:

Larsen CM¹, McCully RB¹, Murphy JG¹, Kushwaha SS¹, Frantz RP¹, Kane GC²

Copyright © 2016 Elsevier Inc. 

PMID:

27291969

DOI:

10.1016/j.amjcard.2016.04.028